Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.64 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.63 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.63 |
| ▸ | EGFR | P00533 | 1/20 | 0.63 |
| ▸ | ESR1 | P03372 | 1/20 | 0.63 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.63 |
| ▸ | FYN | P06241 | 1/20 | 0.63 |
| ▸ | PGR | P06401 | 1/20 | 0.63 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.63 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.63 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1768661 | 1.00 | CYSLTR1 (0.64) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL1115929 | 1.00 | CYSLTR1 (0.64) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL4540937 | 1.00 | CYSLTR1 (0.64) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL1204494 | 1.00 | CYSLTR1 (0.64) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL6109991 | 0.99 | CYSLTR1 (0.63) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL1592792 | 0.99 | CYSLTR1 (0.63) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL6111299 | 0.99 | CYSLTR1 (0.63) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL2076669 | 0.99 | CYSLTR1 (0.63) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL4250432 | 0.93 | CYSLTR1 (0.54) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| Acetic Acid SCHEMBL1204496 | 0.90 | CYSLTR1 (0.74) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105757-A1 | METHOD FOR PREPARATION OF MONTELUKAST ACID IN IONIC LIQUID MEDIUM | HANMI PHARM. CO., LTD. (KR) | 2011-05-05 | — | — | US | claimed |
| US-20090281323-A1 | PROCESS FOR THE MANUFACTURE OF MONTELUKAST SODIUM | GLADE ORGANICS PRIVATE LIMITED (IN) | 2009-11-12 | — | — | US | claimed |
| US-20090182148-A1 | PROCESS FOR THE MANUFACTURE OF MONTELUKAST SODIUM | CHAWLA HARMANDER SINGH PAL | 2009-07-16 | — | — | US | claimed |
| US-11844861-B2 | Topical Montelukast formulations | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2023-12-19 | — | — | US | disclosed |
| US-20220016028-A1 | TOPICAL MONTELUKAST FORMULATIONS | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2022-01-20 | — | — | US | disclosed |
| US-11173117-B2 | Topical Montelukast formulations | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2021-11-16 | — | — | US | disclosed |
| US-20210236423-A1 | TOPICAL MONTELUKAST FORMULATIONS | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2021-08-05 | — | — | US | disclosed |
| EP-2004608-B1 | AN IMPROVED PROCESS FOR THE MANUFACTURE OF MONTELUKAST SODIUM | GLADE ORGANICS PRIVATE LTD (IN) | 2011-09-14 | — | — | EP | disclosed |
| US-20110092708-A1 | PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS THEREOF | MYLAN LABORATORIES LIMITED (IN) | 2011-04-21 | — | — | US | disclosed |
| US-20090281323-A1 | PROCESS FOR THE MANUFACTURE OF MONTELUKAST SODIUM | GLADE ORGANICS PRIVATE LIMITED (IN) | 2009-11-12 | — | — | US | disclosed |
| US-20090281323-A1 | PROCESS FOR THE MANUFACTURE OF MONTELUKAST SODIUM | GLADE ORGANICS PRIVATE LIMITED (IN) | 2009-11-12 | — | — | US | disclosed |
| US-20090182148-A1 | PROCESS FOR THE MANUFACTURE OF MONTELUKAST SODIUM | CHAWLA HARMANDER SINGH PAL | 2009-07-16 | — | — | US | disclosed |
| US-20090182148-A1 | PROCESS FOR THE MANUFACTURE OF MONTELUKAST SODIUM | CHAWLA HARMANDER SINGH PAL | 2009-07-16 | — | — | US | disclosed |
| EP-2004608-A1 | AN IMPROVED PROCESS FOR THE MANUFACTURE OF MONTELUKAST SODIUM | Glade Organics Private Limited (IN) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007116240-A1 | AN IMPROVED PROCESS FOR THE MANUFACTURE OF MONTELUKAST SODIUM | GLADE ORGANICS PRIVATE LIMITED (IN) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11844861-B2 | Topical Montelukast formulations | CYSLTR1, CYSLTR2, SYMPK | CYSLTR1 1/4885CYP2C8 2537/4885CYSLTR2 2/4885 |
| US-11173117-B2 | Topical Montelukast formulations | CYSLTR1, CYSLTR2, SYMPK | CYSLTR1 1/4885CYP2C8 2326/4885CYSLTR2 2/4885 |
| US-20090182148-A1 | PROCESS FOR THE MANUFACTURE OF MONTELUKAST SODIUM | AP1S1, CMA1, MED1 | CYSLTR1 17/4885CYP2C8 2439/4885CYSLTR2 26/4885 |
| US-20110092708-A1 | PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS THEREOF | CMA1, LTC4S, LTA4H | CYSLTR1 4/4885CYP2C8 1889/4885CYSLTR2 5/4885 |
| US-20090281323-A1 | PROCESS FOR THE MANUFACTURE OF MONTELUKAST SODIUM | CMA1, MED1, MPST | CYSLTR1 8/4885CYP2C8 1703/4885CYSLTR2 28/4885 |
| US-20110105757-A1 | METHOD FOR PREPARATION OF MONTELUKAST ACID IN IONIC LIQUID MEDIUM | CYSLTR1, LTC4S, CYSLTR2 | CYSLTR1 1/4885CYP2C8 3488/4885CYSLTR2 3/4885 |
| US-20210236423-A1 | TOPICAL MONTELUKAST FORMULATIONS | CYSLTR1, CYSLTR2, SYMPK | CYSLTR1 1/4885CYP2C8 2326/4885CYSLTR2 2/4885 |
| US-20220016028-A1 | TOPICAL MONTELUKAST FORMULATIONS | CYSLTR1, CYSLTR2, SYMPK | CYSLTR1 1/4885CYP2C8 2537/4885CYSLTR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.